ADVERTISEMENT
Aurobindo Pharma: Motilal Oswal Maintains 'Buy' Citing Multiple Growth Triggers, Sees Upto 18% Upside
Aurobindo Pharma’s diversification and policy tailwinds signal potential upside, says Motilal Oswal, retaining 'Buy' call.
04 Dec 2025, 01:05 PM IST 
Save
Aurobindo Pharma has the highest US generics sales compared to any other listed company in India, with a maximum number of ANDA approvals.
(Representative image. Photo source: Unsplash)
Product development, as well as backward integration for the manufacturing process, has enabled Aurobindo Pharma's healthy profitability despite consistent price erosion (albeit at reduced intensity).
